#249 Brice Challamel: How Moderna is Using AI to Disrupt Modern Healthcare

This episode is sponsored by Oracle. OCI is the next-generation cloud designed for every workload – where you can run any application, including any AI projects, faster and more securely for less. 

On average, OCI costs 50% less for compute, 70% less for storage, and 80% less for networking. Join Modal, Skydance Animation, and today’s innovative AI tech companies who upgraded to OCI…and saved. 

Offer only for new US customers with a minimum financial commitment. See if you qualify for half off at http://oracle.com/eyeonai

In this episode of Eye on AI, Craig Smith sits down with Brice Challamel, Head of AI Products and Innovation at Moderna, to explore how one of the world’s leading biotech companies is embedding artificial intelligence across every layer of its business—from drug discovery to regulatory approval.

Brice breaks down how Moderna treats AI not just as a tool, but as a utility—much like electricity or the internet—designed to empower every employee and drive innovation at scale. With over 1,800 GPTs in production and thousands of AI solutions running on internal platforms like Compute and MChat, Moderna is redefining what it means to be an AI-native company.

Key topics covered in this episode:

• How Moderna operationalizes AI at scale

• GenAI as the new interface for machine learning

• AI’s role in speeding up drug approvals and clinical trials

• The future of personalized cancer treatment (INT)

• Moderna’s platform mindset: AI + mRNA = next-gen medicine

• Collaborating with the FDA using AI-powered systems

Don’t forget to like, comment, and subscribe for more interviews at the intersection of AI and innovation.

Stay Updated:

Craig Smith on X:https://x.com/craigss

Eye on A.I. on X: https://x.com/EyeOn_AI

(00:00) Preview 

(02:49) Brice Challamel’s Background and Role at Moderna

(05:51) Why AI Is Treated as a Utility at Moderna

(09:01) Moderna's AI Infrastructure

(11:53) GenAI vs Traditional ML

(14:59) Combining mRNA and AI as Dual Platforms

(18:15) AI’s Impact on Regulatory & Clinical Acceleration

(23:46) The Five Core Applications of AI at Moderna

(26:33) How Teams Identify AI Use Cases Across the Business

(29:01) Collaborating with the FDA Using AI Tools

(33:55) How Moderna Is Personalizing Cancer Treatments

(36:59) The Role of GenAI in Medical Care

(40:10) Producing Personalized mRNA Medicines

(42:33) Why Moderna Doesn’t Sell AI Tools

(45:30) The Future: AI and Democratized Biotech